GHK-Cu for hair growth: what the evidence shows and how it is used

GHK-Cu is a three amino acid peptide bound to a copper ion that occurs naturally in plasma and declines with age. For hair, the claims are that it enlarges follicles, prolongs the growth phase, increases blood supply to the follicle through VEGF, reduces inflammation around the follicle, and blocks DHT at the scalp. Each has some basis in cell or animal work. None has been shown in a controlled human trial of GHK-Cu alone on pattern hair loss.

The DHT claim is the one most often overstated. The 5-alpha reductase inhibition data comes from in vitro work on the related peptide AHK-Cu, not from GHK-Cu, and no human hormone measurement supports it for either. The follicle size and VEGF effects are better grounded, and they are the reason the compound page lists hair as an emerging indication rather than nothing at all.

The animal data is the solid part. Mouse studies of copper peptides report larger hair follicles and faster regrowth after shaving, consistent with a longer anagen phase. The gene expression work that underpins most GHK-Cu marketing found it shifts thousands of genes toward repair and away from inflammation, which is plausible background for a follicle effect but is not a hair study.

Human data is a few small trials, mostly from the cosmetic industry, reporting increased follicle size and reduced shedding with topical copper peptide products over several months. They are small, short, often lack a proper control group, and the products tested were usually formulations containing other actives alongside the peptide. The compound page summarizes the state of play as: reasonable animal evidence, a few small human studies, not as well proven as minoxidil or finasteride. That is the honest ceiling in 2026.

Worth noting is what the skin evidence does and does not transfer. Controlled human trials showed topical GHK-Cu improved skin thickness, elasticity and fine lines over 12 weeks. Scalp skin is skin, so some benefit to the follicle environment is reasonable to expect. Thicker dermis is not the same as more hair, and vendors routinely cite the skin trials as if they were hair trials.

Topical is the route with the evidence and the one the compound page lists for hair: a 1 to 2 percent solution applied to the scalp once daily, after cleansing and before anything heavier. The powder is sold in 50 and 100 mg vials and reconstituted into a solution; 50 mg in 5 mL gives roughly 1 percent, and the resulting liquid should be clear and blue. Stored in the fridge, a reconstituted solution is used within 4 weeks, which matches the general peptide shelf life rule.

Microneedling is the common upgrade. A dermaroller or pen at 0.5 to 1.5 mm, used once weekly before application, is borrowed from the minoxidil literature, where microneedling plus minoxidil outperformed minoxidil alone in a controlled trial. No equivalent trial exists for GHK-Cu, so the combination rests on the assumption that improved penetration helps a topical that works at all. Patch test first; copper peptides sting on freshly needled skin and irritation is more likely.

Injectable GHK-Cu for hair is a forum practice with no data. Some people inject 0.5 to 1 mg subcutaneously near the scalp or in the abdomen on the theory that systemic effects reach the follicle. There are no human trials of subcutaneous GHK-Cu for any purpose, injection site stinging and bruising are very common, and copper accumulation is a theoretical concern with sustained dosing. For hair specifically there is no reason to think it beats a topical, and several reasons to prefer the route that has at least some evidence.

AHK-Cu swaps the first amino acid of GHK-Cu, glycine for alanine, and is the copper peptide that was actually studied for hair. In cultured human dermal papilla cells, the cells at the base of the follicle that control the growth cycle, it increased proliferation, reduced cell death, raised VEGF and lowered TGF-beta1, all of which favor growth. It also inhibited 5-alpha reductase in vitro. A small Korean clinical study of a topical AHK-Cu solution in men with pattern hair loss reported more and thicker hairs over several months, without a large control group.

That is a thin record, but it is a hair record, which GHK-Cu largely lacks. Many people use both: GHK-Cu for skin and AHK-Cu on the scalp, or a combined serum with roughly 0.5 mg of each. Reported topical use is 0.5 to 1 mg daily, about a 1 percent solution, with results judged at 3 to 6 months. Side effects are scalp irritation, a brief shedding increase in the first weeks, and a blue-green tint on light hair or pillowcases.

Commercial serums and the homemade solutions people mix from vials cluster in a narrow range. Higher is not better: copper peptides irritate skin at high concentrations, and the compound page notes that stinging and bruising climb steeply above 2 mg per mL for injection, with topical irritation following the same curve.

Minoxidil has decades of randomized trials showing increased hair count in pattern hair loss, with 5 percent topical outperforming 2 percent and placebo in men. Finasteride has large controlled trials showing it halts and partly reverses loss by cutting DHT. Both are approved for the purpose. GHK-Cu has mouse data and small pilots. There is no trial putting GHK-Cu against either, so the vendor line that it works as well as minoxidil is unsupported, and a claim that it replaces finasteride is unsupported twice over, since its DHT effect was never shown in a person.

The realistic position is the one the compound page takes: use it as an add-on to a proven treatment, not instead of one. Someone on minoxidil who adds a copper peptide scalp solution is making a low risk bet with a modest possible upside. Someone who drops finasteride for GHK-Cu because a forum said the DHT effect was comparable is trading a known effect for a hoped one. Hair timelines are slow either way; reduced shedding may show in 6 to 8 weeks, and any thickening takes 3 to 6 months of daily use before it can be judged.

If after 6 months of consistent use there is no change in shedding or density, the compound pages say the same thing for both copper peptides: stop. More of the same is unlikely to help.

Topical GHK-Cu is well tolerated. The reported problems are irritation, redness or itching, more likely with high copper content or after microneedling, and contact dermatitis in people sensitive to copper. A brief increase in shedding in the first weeks is reported with most hair treatments as follicles reset. The blue solution can tint light hair and stain pillowcases. Anyone with Wilson disease or another copper metabolism disorder should avoid copper peptides by any route.